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ABSTRACT
Quality of life (QoL) is a complex idea without a
clear consensus definition. Generally speaking,
QoL refers to several subjective measures of
wellbeing that vary by individual and circum-
stance. QoL can decline noticeably as a disease
progresses. This is particularly true for geo-
graphic atrophy (GA), an advanced form of age-
related macular degeneration. GA leads to
vision loss for which there is no currently
approved pharmacological treatment. There is a
lack of qualitative, patient-driven research on
QoL in GA. There is also limited information
available to both patients and physicians about
GA, existing support groups and available
assistive technologies. To address this, we have
collated the experiences of a person with GA
and those of her partner and carer with the
current literature on QoL in GA. We have also
outlined some of the wide range of developing
technologies available to help people with GA
carry out daily tasks and hobbies. It is clear that
support, whether through informal or struc-
tured care, is vital to the wellbeing of people
with GA. Despite this, the general public are
often unaware of care work, which may result in
this integral role being undervalued and under
acknowledged. Furthermore, it is apparent that
the general public have fundamental misun-
derstandings around what vision loss entails
and are unaware that blindness is a vast spec-
trum. This feeds into the seemingly paradoxical
mix of isolation and dependence on others that
often results from GA and vision loss. Through
this qualitative examination of a patient’s
experiences, we hope to inform and educate
both patients and physicians about GA as well
as precipitate discussion around the frameworks
that should be in place to support both newly
diagnosed and long-term patients with GA and
other retinal diseases.
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Asking someone about their ‘quality of life’ is
one way to understand their general wellbeing.
Quality of life can mean different things to
different people. For some people it may mean
being able to do what they want to. For others it
may include feelings such as happiness. Dis-
eases that cause people to lose their vision can
have a very big impact on quality of life. Geo-
graphic atrophy is an eye disease that leads to
loss of vision and has no cure. In this article,
Dolores, a person with geographic atrophy, Bill,
her husband and carer, and Jill, a quality of life
researcher, discuss how geographic atrophy can
change quality of life. Vision loss often means
that people are unable to keep up their hobbies
and do daily tasks, like shopping or cooking.
Learning to use smartphone apps and gadgets
can help many people with their hobbies and
tasks. Feeling alone also makes quality of life for
people with geographic atrophy worse. The help
and understanding of others—including
friends, family and doctors—are very impor-
tant. Treatment plans for patients with vision
loss need to consider all parts of a patient’s life.
Training for doctors should continue to
emphasise that people with geographic atrophy
are more than just eyes that cannot be treated.
Keywords: Age-related macular degeneration;
Geographic atrophy; Patient perspective;
Qualitative; Quality of life; Retina
Key Summary Points
Geographic atrophy (GA) is an eye disease
that leads to irreversible vision loss, with
no currently approved pharmacological
treatment.
There is a lack of qualitative, patient-
driven research on quality of life (QoL) in
patients with GA.
To address this, three people—a person
with GA, her partner and carer, and a QoL
researcher—have collated their
experiences alongside some of the current
literature on QoL in GA.
We found that although the support of
others and use of assistive technologies
are vital to the QoL of people with GA,
many people are unaware or unable to
access these resources.
The development of integrated care
frameworks that consider the patient
holistically will be critical to improving
and preserving patient QoL in the future.
DIGITAL FEATURES
This article is published with digital features,
including a summary slide, video and slide
deck, to facilitate understanding of the article.
To view digital features for this article go to
https://doi.org/10.6084/m9.figshare.14573511.
INTRODUCTION
What is Quality of Life?
Quality of life (QoL) does not have a consensus
definition and is recognised to be a complex
concept [1]; although there are a number of
definitions for QoL, they are not universally
agreed. QoL can be defined using a range of
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domains, including psychological wellbeing
and happiness, life satisfaction, physical health
and function, and social role and expectations.
The World Health Organization defines QoL as
‘‘an individual’s perception of their position in
life in the context of the culture and value sys-
tems in which they live and in relation to their
goals, expectations, standards and concerns’’
[2]. Karnofsky outlined QoL in patients with
cancer as a ‘‘patient’s subjective improvement
in terms of mood and attitude; general feelings
of wellbeing; and activity, appetite, and the
alleviation of distressing symptoms, such as
pain, weakness, and dyspnea’’ [3]. Spitzer’s
Quality of Life Index is a tool that was devel-
oped in 1981 to assess QoL health outcomes in
patients with chronic disease and states that
QoL variables ‘‘should include physical, social,
and emotional function; attitudes to illness;
personal features of patients’ daily lives,
including family interactions; and the cost of
illness’’ [4]. Some health agencies (such as the
US Center for Disease Control and Prevention)
use the term ‘health-related quality of life’, also
known as HRQoL, which specifically refers to
the aspects of QoL that have been shown to
directly affect physical or mental health [5]. In
older populations (C 65 years), key QoL themes
include maintaining social relationships, the
ability to undertake hobbies, good health and
mobility, and independence [6]. Ultimately,
QoL refers to a highly subjective measure of
patient happiness and may vary by individual
and circumstance [6].
In addition to the lack of a concrete defini-
tion, there are challenges regarding how to
specifically measure and interpret QoL. Physi-
cians often radically underestimate the effect of
visual impairment on QoL [7]. Despite this,
most measures of QoL are based on the opinions
of physicians rather than the opinions of people
for whom QoL is measured, limiting their rele-
vance to patients [8]. In response to this prob-
lem, an emerging set of questionnaires are being
developed that use a ‘bottom-up’ design based
on patient input [9]. Bottom-up questionnaires
tend to use more appropriate and less clinical
language and contain measures that are con-
sidered relevant to patients [9]. The validity of
content is one of the most important properties
of tools that measure patient-reported out-
comes: the COSMIN methodology for assessing
content validity includes criteria on content
relevance, comprehensiveness and comprehen-
sibility for patients [10]. Furthermore, the Food
and Drug Administration (FDA) guidelines for
the development of patient-reported outcome
instruments (currently under consultation)
emphasise the importance of patient engage-
ment and patient comprehension when creat-
ing tools to measure QoL [11]. However, FDA
guidelines also specify internal consistency as
one of their essential criteria for the approval of
patient-reported outcome instruments [12];
some patient population-based measures, such
as the World Health Organization Quality of
Life Instrument-Older Adults Module (WHO-
QOL-OLD), have failed to meet internal con-
sistency criteria, which may limit their use as
quantitative tools in research [8]. When dealing
with approved tools used to measure QoL, both
the qualitative and quantitative aspects must be
considered.
Interest in QoL research has increased with
time: in a PubMed search of publications in
2013 including the term ‘quality of life’, there
were approximately 4000 results [13], whereas
in 2020 there were over 33,000 results (searches
performed on 1 February 2021). Increased
interest in QoL may reflect a growing awareness
that clinical outcomes do not always reflect or
resonate with patient outcomes and expecta-
tions. It is clear that QoL is a rapidly growing
field and will yield important insights into
patient wellbeing as the quantity of research
expands.
What is Geographic Atrophy?
Geographic atrophy (GA) is an advanced form
of age-related macular degeneration (AMD) that
is also known as advanced ‘dry’ AMD [14]. GA
leads to progressive, and at present irreversible,
loss of vision [14]. Vision loss is caused by the
death of photoreceptors, which are specialised
cells in the retina that convert light energy into
visual signals [15, 16]. Photoreceptor death is
accompanied by loss of the retinal pigment
epithelium and the choriocapillaris, which
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regulate the photoreceptor layer and supply
oxygen to the retina [17–19]. GA affects around
5 million people globally and accounts for
roughly one-quarter of legal blindness in the
USA and the UK [17, 20].
GA has quite a variable clinical presentation,
but often begins as a single lesion in the outer
fovea [21]. The fovea is a region of the retina
that is responsible for detailed vision and has a
high density of photoreceptors [22]. Thus,
damage to the fovea reduces one’s ability to see
clearly. Anatomical changes in the eye, such as
the presence of drusen (small yellow–white
lesions), are also associated with AMD; their
presence increases the risk of progression to GA
[23, 24]. Inflammation is also thought to play a
key role in the development of GA, though the
exact mechanism is unclear [14, 17, 25].
Although there are lifestyle changes that a
patient can make to reduce the risk of devel-
oping GA or to slow its progression, such as
quitting smoking or taking nutritional supple-
ments [26], there is currently no approved
treatment for GA.
How Does Geographic Atrophy Affect
Quality of Life?
GA has a profound effect on QoL, which can be
quantitatively assessed using patient question-
naires or patient-reported outcome measures.
The effect of GA on QoL is comparable to that
reported among patients with advanced pros-
tate cancer or severe cerebrovascular accident
and worse than that reported among patients
with chronic obstructive pulmonary disease or
AIDS [7, 27]. Despite this heavy burden for
patients, many physicians may underestimate
the impact of GA on QoL. One study quantified
the effect of AMD on QoL using ‘utility value’—
a number representing the proportion of one’s
life expectancy that a person would willingly
trade in order to return to normal health [7].
The study compared these values for patients
with AMD against those of their treating
physicians (who were asked to imagine that
they had AMD). Patients with advanced AMD
reported that they would trade an average of
60% of their remaining life expectancy to return
to normal health [7]; their treating physicians
underestimated this number by up to 97% [7].
GA is associated with a reduction in inde-
pendence and mental wellbeing. Larger areas of
GA are associated with decreased visual acuity,
hindering the ability to carry out daily tasks
[28–31]. GA also reduces one’s ability to recog-
nise faces [32, 33], and reading speed decreases
as the GA lesion increases in size [31, 34]. Crit-
ically, GA severely impacts a patient’s ability to
drive, which limits their freedom to travel,
reducing their independence [35]. Both AMD
and GA increase the risk of depression and
susceptibility to falls and injuries as a result of
poor visual acuity [20]. Patients with GA have
reported frustration about their lack of inde-
pendence as well as needing to seek help from
others [29].
There is relatively little qualitative research
focusing on the effects of GA on QoL from a
patient’s perspective. Furthermore, commonly
used measures of QoL in GA may not be rele-
vant to the lived experiences of patients, as
much of the focus is on measures of visual
function rather than experience of life beyond
vision. Some standardised questionnaires, such
as the Impact of Vision Impairment (IVI) ques-
tionnaire, do include measures beyond visual
function: the IVI comprises three subscales:
‘reading and accessing information’, ‘mobility
and independence’ and ‘emotional wellbeing’
[36]. However, many questionnaires use abso-
lute numerical scales, which may not be inter-
preted in the same way by all patients and may
not reflect the day-to-day variability of their
QoL. In addition, daily questionnaires for long-
term QoL assessment have not been well
examined, and therefore may be unsuitable for
tracking QoL changes over time.
An alternative and potentially more relevant
way of examining the impact of disease on
someone’s QoL is simple—ask the person
directly. To address the relative paucity of
qualitative information on what it is actually
like to live with GA and to care for someone
with GA, we—a person with GA (Dolores Cas-
well), her husband and carer (William Caswell,
henceforth referred to as Bill) and a QoL
researcher (Jill Carlton)—have worked together
to interweave personal perspectives and
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experience with a review of current literature on
QoL in GA. These conversations are organised
into different themes, ranging from diagnosis to
expectations of future treatment. Through this
qualitative examination of GA, we hope to
inform and educate patients about what to
expect after a GA diagnosis and the types of
help that are available and to outline the cur-
rent unmet needs facing patients with GA.
A PATIENT PERSPECTIVE ON GA
Dolores Caswell was diagnosed with GA in 2014
and is based in Canada. She has recently moved
from Kelowna, BC, to Vancouver, BC, with her
husband. The following section is driven by her
experiences with GA (in italics) and supported
by the scientific literature on vision loss, QoL
and GA.
My Experience of GA
I Hope I’m at the Plateau of Visual Loss, but I
Don’t Know
GA is a chronic and progressive disease whereby
damage to the retina gradually reduces the
ability to see over time [37]. However, despite its
known effect on vision, changes in visual acuity
as measured using traditional optician’s eye
charts do not correlate well with GA progression
[38]. Alternative measures of visual function
(such as the ability to see differences in bright-
ness levels, also known as ‘contrast sensitivity’)
are very important to QoL in GA [39]. These
measures diminish as GA progresses, even when
‘normal’ visual acuity is maintained [40].
Research also indicates that the spread of GA is
faster in the periphery than in central vision
[38].
For me personally, a good day is sunny, and
light makes a huge difference. Shadows and
greyness make the day worse because they
affect the contrast between objects, people and
scenery. I find that my vision has become hazy
in the periphery as my GA has progressed.
I feel some uncertainty around the future of my
vision, as I believe there has been a lot of
damage to my retina—I am not sure whether
any future treatments could help me and my
vision.
Being able to understand and anticipate
changes in vision beyond simple visual acuity is
very important to fully understand GA. It is
clear that some patients lack information
around their expected prognosis; this may be
due to the lack of currently available treat-
ments, which leads ophthalmologists to dis-
charge patients upon diagnosis with little
further advice. The initial shock of diagnosis
may prevent patients from effectively absorbing
information about their condition. Further-
more, discharged patients who are not routinely
seen at clinics do not receive updated informa-
tion about their condition or new treatment
options. Providing patients with more knowl-
edge about the underlying cause of their GA
may assist in managing expectations about how
their vision may change over time. In addition,
systematic follow-up care could ensure that all
patients are able to understand their condition
and its prognosis.
Blindness is a Word that Confuses People
I feel that most people truly do not understand
what blindness is, and believe that being leg-
ally blind means that you are totally blind; you
have to explain yourself over and over again. I
worry that people think that if I walk past
them without saying anything I must be
snooty, whereas the truth is that I am unable
to recognise them.
Up to 42% of all people with GA are classified
as legally blind [20, 41]. Despite the cultural
understanding of blindness typically meaning
‘unable to see’, from a scientific perspective
legal blindness refers to a visual acuity of 20/200
(EU equivalent 6/60) or worse in the better
seeing eye, which is the equivalent of seeing at
20 feet what someone with ‘normal’ visual
acuity could see at 200 ft (or seeing at 6 m what
someone with normal visual acuity could see at
60 m). An alternative definition of legal blind-
ness that is sometimes used is an eye
chart measurement of 20/400 (EU equivalent
6/120) [20, 41]. Visual ability is not constant
across the retina, and a person may have trouble
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with peripheral vision but still have central
vision or vice versa [42].
General lack of understanding around what
the word ‘blindness’ means can also lead to
confusion about how best to address the vision
problems that result from GA. Although mag-
nification (using a hand-held glass, spectacle
magnifiers or a 2–10 9 telescope) is commonly
used to help address vision problems [43], it is
not always useful for people with GA.
I find that as my GA has advanced, magnifi-
cation just blurs everything. However, because
magnification works for other people with
macular degeneration that I know, other people
assume that it will work for me too. Contrary
to common knowledge about magnification, I
find that smaller print is better than the large
cards and large print that people typically use
to increase accessibility for those with vision
problems.
The language used to discuss GA is also
important when it comes to improving general
understanding: terms like ‘vision loss’ may be
more informative than ‘blindness’. Further-
more, it is clear that the standard tools used in
public spaces to improve accessibility for those
with vision loss may not be suitable for people
with GA and that alternative options should be
explored.
There Were Times When I looked at a Person
and Their Nose Would Relocate to Another
Part of Their Face
People who have vision loss may experience
unexpected side effects, including visual hallu-
cinations—known as Charles Bonnet syndrome.
The symptoms of Charles Bonnet syndrome
vary from simple geometric figures to animals
in motion [44] and may be associated with lar-
ger areas of GA [44].
Personally, I found my experience of Charles
Bonnet syndrome more interesting than
frightening, but it may have helped that I was
told about it being a potential side effect during
my prior participation in a clinical trial.
Some people do find the hallucinations
frightening: close to 30% of people report
experiencing some distress as a result of the
hallucinations, and they are more likely to
occur for people who live alone [44, 45]. In
addition, people may feel reluctant to discuss
symptoms such as hallucinations due to fear of
being considered ‘senile’; therefore, the preva-
lence of Charles Bonnet syndrome may be
higher than that reported in the literature.
Providing a clear explanation for these hal-
lucinations has been shown to relieve the anx-
iety associated with their presence [46]; this
demonstrates the importance of targeted
patient information for improving mental
health, and therefore QoL [46]. The need to
provide such information extends to treating
physicians, many of whom are unfamiliar with
Charles Bonnet syndrome [46]. Better education
around the possible side effects associated with
GA could greatly reduce the anxiety associated
with vision loss.
The Impact of GA on My Quality of Life
Despite Bill Being Beside Me Now, I Cannot See
His Face: It’s All in Shadow
GA has a substantial effect on the ability to
recognise faces, and the impact becomes more
noticeable as the disease progresses [29, 32]. The
ability to recognise faces is central to social
interaction; in young adults particularly,
reduced facial recognition ability is associated
with increased social anxiety [47].
I am a very social person, and the one thing
that bothers me the most is that I can’t see
people clearly—if I stand very, very close, I can
hold their face in my hands and peer at them—
then I can see. But of course, I can’t do that to
just anyone. The fact that I cannot see faces
clearly is one thing that really disturbs me.
The lasting emotional and social impact of
not being able to clearly see your loved ones is
unclear, but there is no doubt that it causes at
least some level of distress.
All My Hobbies Have Pretty Well Disappeared
People with ‘low vision’ are often concerned
about their reduced ability to read; one study
showed that 66.4% of people who had sched-
uled a low-vision appointment in the USA were
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worried about their reading ability [48]. How-
ever,\ 10% of people with low vision are con-
cerned about their reduced ability to partake in
hobbies more generally [48], which suggests
that for people with low vision (as opposed to
GA), loss of hobbies is not an issue of note. It is
not surprising that research indicates that the
hobbies of people with GA may be affected to a
greater degree than those of the general low
vision population: half of all subjects in one
study of people with GA reported that GA had a
negative impact on hobbies and leisure activi-
ties—a much higher proportion than that
reported in the general low-vision population
[30]. Fortunately, some existing hobbies can be
adapted for low vision—for example, other
people have reported using digital technology
such as eBook readers to magnify book text or
devising clever methods of fishing that use the
sense of touch rather than sight [29].
Personally, I find that with GA, my ability to
take part in hobbies has been noticeably
reduced. Although I can play golf with some-
one watching the ball for me, knitting and
alternative art are no longer possible—I used to
be an artist and I miss art. Since my diagnosis,
I don’t have any new hobbies, none at all.
Hobbies never last forever, but when you have
GA they stop earlier than you thought they
would.
Many people with GA find that they can no
longer enjoy their hobbies; better education
around assistive technologies that are currently
available, and specific techniques that can be
learnt, may prolong the amount of time people
can continue with their hobbies and could
greatly improve QoL.
I’m More Isolated, I Have to Depend on Others
GA has a substantial effect on an individual’s
mobility and independence [35, 49]. One of the
main reasons for reduced independence for
people with GA is its effect on the ability to
drive; over half of all people with GA who have
a valid driving licence do not feel confident
driving during the day and the majority would
not drive at night [35]. In one study, 66.7% of
people diagnosed with GA became ineligible to
drive within a median time of 1.6 years [20].
Many people with GA report not being able to
drive as one of the key factors that reduces their
QoL and independence [29, 30].
I feel strongly that my quality of life has gone
down because I don’t drive: it has taken away
my independence. Another thing that worries
me is being taken advantage of financially.
When we sold our house recently, I couldn’t
read any of those forms and I had to really
trust my partner. There is no such law in
Canada that would mean my signature would
not be legal if it hadn’t been witnessed—there
should be.
Despite that fact that many people with
vision loss have to depend on others far more
than those without vision loss, feelings of
loneliness are common [50]. Depression and
anxiety are not significantly associated with
general AMD [51], but up to 25% of people with
severe vision loss from AMD (such as GA) may
experience depression [52], and the incidence of
depression is strongly associated with the
severity of vision loss [53].
Although we have a lot of good friends, I think
we are maybe not included in the same way, as
I can’t do a lot of the things they do; new
friends just don’t understand, they’re busy
with their own lives and don’t have the time to
bother with someone who is disabled. The
effect GA has on independence can be an iso-
lating experience, as you feel like you’re sepa-
rate from your family and friends, while
depending on them to complete daily tasks like
shopping or travelling. Even your personal
finances may require support from someone
else.
Independence and social interaction are very
important for mental wellbeing. It is very
important to ensure that people with GA are
able to access the support of others when nee-
ded, but also that they are aware of the different
ways in which they can carry out their daily
tasks without the need for outside help.
I Feel Vulnerable When I Have My Cane, I Feel
Different
The white cane is a worldwide symbol for vision
impairment and plays a key role in allowing
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people with vision loss to navigate indepen-
dently [54, 55]. However, the white cane may
also cause people to feel self-conscious and
family members to become overprotective [56].
Feelings of shame or embarrassment may be
particularly pronounced when encountering
people who knew them before the onset of
vision loss [55]. Importantly, research has
shown that there is a lack of well-described
protocols and studies on how to train and ori-
entate people on the use of a cane [57].
I find that if I have my cane, it makes a huge
difference, and most people are very consider-
ate. I should be using the cane more than I do,
but the cane makes me feel vulnerable. I was
first told about canes by someone who specif-
ically told me that you are vulnerable with the
cane and that has stuck with me.
Producing high-quality guidelines on how to
introduce canes to patients (for physicians) and
how to use canes for independence and mobil-
ity (for people with low vision) may be an
effective way to restore some degree of confi-
dence and independence for people with GA.
Somewhere Along the Line It Gives You
Strength, if You Want It
I do not want people to feel as though there is
no hope or joy for people with GA—I am a
happy person and optimistic. While I miss the
hobbies I used to have, it doesn’t make me
sad—I was just very lucky I was able to do
them when I could. I think it hardens you in a
sense, when you lose a sense—and I have
found that my memory has improved because I
have to memorise so many things.
Although there is little to no research on the
effect of vision loss on working memory in older
populations, research has indicated that chil-
dren with vision loss have a higher working
memory capacity than children without vision
loss [58].
The support from my family and my husband,
Bill, has been great, but I do think that it’s very
sad for people who are alone, and very hard.
It is clear that for people in isolation, dealing
with vision loss is challenging and feelings of
loneliness are common [50]. Creating systems
that support people and provide independence
for those without close family or friends could
greatly increase the QoL of specific populations.
My Experience of Clinical Research
and Expectations of Future Treatment
Several years ago, Dolores Caswell took part in a
clinical trial for a (now terminated) potential
treatment for GA [59]. This trial examined the
effect of lampalizumab on patients with GA but
was terminated as it did not meet its primary
endpoint of reducing mean change in GA lesion
area. This next section discusses the impact of
clinical trials on a participant’s QoL, driven by
Dolores’ personal experiences (in italics) and
supported by the scientific literature.
It Was a Good Experience, It Was Just
Unfortunate that It Was Not the Answer
Although there is limited research on why
people choose to participate in clinical trials, or
on the effects of clinical trials for patients
beyond treatment, one survey has found that
most people participate because they would like
to contribute more to science (69%) and/or
learn more about their condition (51%) [60].
Sixty-five per cent of people reported feeling
more educated about their overall health as a
result of trial participation, improving their QoL
[60].
I learned a lot from taking part in the clinical
trial. The trial helped me connect with a
number of people who had helpful information
and advice about technology that I could use to
improve my QoL. However, for people with GA
without such connections, from the time they
are diagnosed, they basically don’t have any
help. Unfortunately, the trial stopped sud-
denly, saying that the results were inconclu-
sive, and I received no further information.
Personally, I am also concerned about the
hereditary aspects of GA, as I’d hate to pass
this on to my children. I do worry any time my
family say that their eyes are changing dras-
tically, although I think they all know to ask
their ophthalmologist to look into AMD or GA.
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Although GA is not a ‘classic’ inherited
condition, there are some genetic risk factors for
the development of GA, most notably a poly-
morphism in the ARMS2 (age-related macu-
lopathy susceptibility) gene [61].
Overall, it is fairly uncommon for patients to
be notified of clinical trial results, whether
positive or negative, unless it is considered to
influence their future care, despite clinical trial
participation often requiring a substantial time
investment on the part of the participant [62].
Although clinical trial participation may facili-
tate access to information and support, it
should not be a prerequisite. It is vital to pro-
vide patients with a platform through which
they can access information about GA and
ongoing research without necessitating their
participation.
I Would Worry About Surgery Unless It Was
The Final Answer
The range and type of treatment options are
important to patient QoL. If patients are happy
with the method of treatment administration,
they are likely to take the treatment regularly
[63]—missing treatments for vision loss can
result in irreversible damage, and thus irre-
versible loss of QoL. That said, research shows
that people with vision loss typically prioritise
maintaining their vision over concerns about
treatment type or frequency [64].
Although there is currently no treatment for
GA, I think I would feel safer with an injection
because I would know that I was receiving the
right dose. However, an oral compound would
be easier and less invasive and would have less
impact on my QoL. When I received injections
in my eye during the clinical trial, the incon-
venience of it all had an impact on my life. I
feel that if they could have maintained my
vision 6 years ago, it would have been won-
derful, and if there was anything that could
improve my eyesight, we would do it—
regardless.
As more treatments for AMD (the underlying
disease that can lead to GA) emerge, patients
and their physicians may need to choose
between treatment efficacy and the invasiveness
of certain methods of administration (such as
surgery or injection), both of which affect QoL.
The method of treatment administration and its
effect on QoL should be considered when
developing new treatments for GA.
EXPERIENCES OF BILL CASWELL
AS A CARER
Bill and Dolores Caswell have been married for
64 years. The next section of this review is dri-
ven by Bill’s experiences after Dolores’ diagnosis
(in italics) and supported by the literature on
caring for people with vision loss.
It’s a Fact of Life, and We Are Learning
to Live with It
Close to half of all people with vision loss make
use of ‘informal’ care [65]. In Portugal, it is
estimated that 390 h per informal carer, per
annum, is spent caring for people with vision
loss [65]. However, when vision loss approaches
that of a person with GA (20/250 or worse), this
can increase to 4892 h per carer per annum
[66]—almost three times longer than a standard
37.5-h working week (1950 h/annum).
We recently moved to Vancouver, an unfa-
miliar area, which can pose challenges for
those with vision loss; moving into a new res-
idence is hard as other people may not under-
stand our specific needs and could think
Dolores is being cold towards them. Recently,
we were on a crowded street and Dolores
couldn’t see me; she was very worried as she
felt alone in strange surroundings—but I made
sure she was never out of my sight. While the
burden on carers can be substantial and is
undeniable, and I do think I am a carer, I don’t
focus on that—it’s just the way life is and we
do a lot of things together.
I believe that Dolores’ loss of vision has
affected me less than if she became sight
impaired earlier in her life; I think it is
important to note that Dolores’ situation is
easier than for many people. If it had happened
when we were younger, it would have had more
influence on us. Overall, it’s not a hardship for
me, but a fact of life. Without doubt, it’s a
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different commitment you’ve got to make to
your partner.
Almost half of young people who care for
their parents or other relatives report having a
mental health issue and they miss considerably
more days of higher education than those
without caring responsibilities [67]. The impact
of caring for parents on the reported mental
health of middle-aged carers (50–58 years) is
also substantial [68]. For some people, caring for
a partner may have greater adverse effects on
their mental health than caring for a parent
[69].
The vital role of informal and often unpaid
carers frequently passes unnoticed. However, it




IMPROVE QOL IN GA
Although there is currently no treatment for
GA, there are a number of technologies that
may help people with GA to carry out daily
tasks and engage with their hobbies. While
there are some low-tech solutions to some issues
associated with GA, such as colour-contrast
chopping boards to help when chopping veg-
etables, information about modern technology
is often difficult for older populations who are
affected by GA to access. Below, we have col-
lated some of the many technologies that are
available to help people with GA.
The PenFriend is a device that allows people
to attach ‘audio labels’ to items around the
house, from washing instructions to colours,
toiletries, spices and paperwork [70]. The most
recent versions of the PenFriend also allow users
to listen to audio books. At the time of writing,
the Royal National Institute of Blind People
(RNIB) PenFriend 3 was priced at £95.99 [70]. In
addition, the RNIB website also stocks specially
adapted recreational activities for people with
vision loss, including tactile backgammon and
chess sets, braille sudoku and automatic needle
threaders.
There are also several applications on
smartphones that can help people with vision
loss—Siri (Apple) is a well-known smartphone
assistant, but almost all smartphones come with
some sort of proprietary assistant software
nowadays (Samsung uses Bixby, Microsoft uses
Cortana, Amazon uses Alexa and Google uses
the Google Assistant). Smartphones and other
voice-activated assistants can be used to play
music, set calendar notifications, make phone
calls, send texts, read out information present
on the screen and more. The ‘Be My Eyes’ app
connects people who are blind or have low
vision with sighted volunteers who can provide
visual assistance through a live video call: live
volunteers can read menus, find street signs and
respond to questions that require a greater
degree of vision to answer. The ‘Seeing Eye GPS’
phone app (available in the USA and Canada)
provides descriptive verbal navigation for peo-
ple with low vision [71].
For those with vision loss who can read
braille, there are options to connect braille
keyboards and displays to computers, and some
smartphones are compatible with braille
tables and displays [72], allowing people to use
braille to enter text (such as the ‘TalkBack’
braille virtual keyboard, available on Android
and Apple devices). Standard computer key-
boards can also be adapted with larger keys or
high-contrast stickers to improve visibility.
Although magnifiers are not useful for all
people with GA, especially those with more
advanced vision loss, they remain a common
and helpful aid for many. Many smartphones
have inbuilt cameras capable of magnifying text
and images ‘live’. Furthermore, the recent move
towards light detection and ranging (LiDAR)
scanner technology means that some smart-
phones are now capable of detecting the prox-
imity of an object, facilitating safe navigation
around crowded spaces [72].
However, technological solutions can be
expensive, with magnifiers and audio readers
costing upwards of £1000 and apps requiring
access to, and familiarity with, a smartphone.
Depending on one’s geographical location,
there are schemes to loan such devices; this
emphasises the vital role of support communi-
ties and accessibility to such groups. There are a
Ophthalmol Ther
number of support groups available for people
with vison impairment. A select number of
groups are summarised by geographical region
in Table 1.
A major limiting factor for many people with
GA is the lack of information about products or
technologies that could assist in daily tasks;
providing consistent and up-to-date informa-
tion on currently available technology could
vastly improve QoL for many people.
UNMET NEEDS AND FUTURE
PERSPECTIVES ON QOL IN GA
Current Unmet Needs For Patients With
GA
GA has a notable disease burden for patients.
The loss of vision can be traumatic and impacts
many aspects of a patient’s life, including social
relationships, hobbies and daily activities.
Although there are schemes and technologies
that can support patients with GA, many
patients may not be aware of them. Support
systems may be inadequate or, in some cases,
unavailable, to patients with a new diagnosis of
GA; patients must often find resources them-
selves, which can be particularly challenging if
they are isolated. It is clear that greater access to
information about GA is fundamental to
improving patient QoL. While at present there
is no approved treatment for GA, involving and
informing people with GA about the process of
retinal health research may improve outcomes
for both patients and researchers.
Current Unmet Needs For Physicians
Treating GA
Physicians lack a consistent framework to guide
and help patients with GA post-diagnosis, and
there is local variation in the extent of support
available. Some professional bodies, such as the
Royal College of Ophthalmologists, recom-
mend offering ‘low vision’ support to patients
with GA if vision loss is impacting upon their
independence and lifestyle at the time of
Table 1 Select list of support groups for people with vision impairment
Support group Location Website
Royal National Institute of Blind People (RNIB) UK https://www.rnib.org.uk/
Macular Society UK https://www.
macularsociety.org/
Canadian National Institute for the Blind (CNIB) Canada https://www.cnib.ca/
Deutscher Blinden und Sehbehindertenverband (DBS) Germany https://www.dbsv.org/
Pro RETINA Germany https://www.pro-retina.
de/
Spanish National Organisation of the Blind (ONCE) Spain http://www.once.es
American Foundation for the Blind (AFB) USA https://www.afb.org/
National Federation of the Blind (NFB) USA https://www.nfb.org/
European Blind Union (EBU) Europe http://www.euroblind.
org/




African Union of the Blind (AFUB) Africa http://www.afub-uafa.
org/
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diagnosis [73]; however, as patients may be
discharged from care after their initial diagno-
sis, some will miss out on physician-facilitated
access to low vision support as their condition
worsens over time. A standardised framework
should be developed to support post-diagnosis
care for patients with GA, starting with
increasing access and knowledge about com-
munity resources and technology. It is impor-
tant that this framework includes a way for
physicians to stay informed and in touch with
their local vision impairment community,
allowing them to easily refer their patients for
accessible support options and to remain con-
nected with developments beyond just the
treatment of the disease. The impact of GA
extends beyond the eye into the psychosocial
aspects of health and wellbeing; although the
clinical signs and symptoms of GA are similar
across patients, the way in which GA affects a
person’s life will vary by individual. Training for
physicians must continue to emphasise that
patients with GA are not simply eyes that can-
not be fixed—empathy, care and consideration
for each person as a whole are vital.
Future Perspectives
The development of standardised programmes
to improve access to technologies and support
could greatly improve the QoL of patients with
GA. The impact of GA (and other retinal dis-
eases) extends far beyond the physiology of the
eye, affecting mental health, physical ability
and independence. Any standardised training
or support programme must acknowledge the
need to see beyond the eye. Critically, while
support does exist for patients with ‘low vision’,
there is local variation in the nature and avail-
ability of low vision services; integrating low
vision support networks into standard care
frameworks could help to improve the consis-
tency, quality and accessibility of post-diagnosis
support.
Furthermore, educational programmes could
enhance physicians’ understanding of the
available options for their patients; it is crucial
that such programmes target physicians of all
experience levels and not just new doctors and
researchers. Similar programmes should also be
developed for patients, carers and the general
public.
CONCLUSIONS
For QoL in GA to improve, physicians must be
prepared to see beyond anatomy and consider
patients holistically—looking beyond whether
they can be ‘treated’ and focusing on how they
can be supported. Promoting active dialogue
between patients and physicians may help to
build empathetic understanding and drive the
development of programmes aiming to improve
QoL for patients with GA. Furthermore,
improving, developing and integrating educa-
tional programmes and workshops about GA for
patients, carers physicians and the public alike
would facilitate general understanding and
awareness. These programmes could improve
the confidence of patients, the knowledge of
physicians and the ability of friends and family
to support their loved ones with GA.
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